We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $2.21B
1-Year Est. Return 431.26%
This Fund
S&P 500
This Quarter Est. Return
+47.82%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$808M
AUM Growth
+$260M
Cap. Flow
-$29.2M
Cap. Flow %
-3.62%
Top 10 Hldgs %
40.15%
Holding
122
New
39
Increased
28
Reduced
16
Closed
27

Top Buys

Rank Stock Value
1
XENE icon
Xenon Pharmaceuticals
XENE
+$17.4M
2
VERA icon
Vera Therapeutics
VERA
+$16.7M
3
ONC
BeOne Medicines Ltd
ONC
+$13.2M
4
AUTL
Autolus Therapeutics
AUTL
+$11.4M
5
KURA icon
Kura Oncology
KURA
+$10.5M

Top Sells

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$41.6M
2
CBAY
Cymabay Therapeutics
CBAY
+$25.8M
3
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$18.9M
4
LIAN
LianBio American Depositary Shares
LIAN
+$16.9M
5
VKTX icon
Viking Therapeutics
VKTX
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 70.51%
2 Miscellaneous 29.3%
3 Financials 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.7B
$66.4M 8.22%
+700,000
New +$65M
MRNA icon
2
PUT
Moderna
MRNA
$58.1B
$42.6M 5.28%
+400,000
New +$40.3M
APGE icon
3
Apogee Therapeutics
APGE
$39.3M 4.87%
592,093
+55,000
+10% +$2.4M
XENE icon
4
Xenon Pharmaceuticals
XENE
$5.79B
$36M 4.46%
837,387
+377,387
+82% +$17.4M
MDGL icon
5
Madrigal Pharmaceuticals
MDGL
$12.5B
$30.7M 3.8%
115,000
+15,000
+15% +$3.53M
TEVA icon
6
CALL
Teva Pharmaceuticals
TEVA
$42.4B
$23.4M 2.89%
1,655,000
+255,000
+18% +$3.21M
CRNX
7
DELISTED
Crinetics Pharmaceuticals
CRNX
$22M 2.72%
470,000
+22,905
+5% +$896K
AUTL
8
Autolus Therapeutics
AUTL
$596M
$21.5M 2.67%
3,375,000
+1,824,592
+118% +$11.4M
CLDX icon
9
Celldex Therapeutics
CLDX
$3.12B
$21.4M 2.65%
510,000
+110,000
+28% +$4.52M
ACLX
10
DELISTED
Arcellx
ACLX
$20.9M 2.58%
300,000
-40,000
-12% -$2.54M
VERA icon
11
Vera Therapeutics
VERA
$2.59B
$20.3M 2.51%
+470,000
New +$16.7M
INZY
12
DELISTED
Inozyme Pharma
INZY
$20.2M 2.51%
2,642,519
+756,717
+40% +$4.15M
TEVA icon
13
Teva Pharmaceuticals
TEVA
$42.4B
$19.8M 2.45%
1,400,000
-500,000
-26% -$6.3M
KURA icon
14
Kura Oncology
KURA
$1.18B
$15.6M 1.93%
730,492
+538,957
+281% +$10.5M
SYRE icon
15
Spyre Therapeutics
SYRE
$7.85B
$15.6M 1.93%
410,000
-107,554
-21% -$3.12M
VRNA
16
DELISTED
Verona Pharma
VRNA
$13.2M 1.63%
817,833
+254,009
+45% +$4.39M
ONC
17
BeOne Medicines Ltd
ONC
$40.5B
$12.8M 1.59%
+82,143
New +$13.2M
CERE
18
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$12.7M 1.57%
300,000
-450,000
-60% -$18.9M
NRIX icon
19
Nurix Therapeutics
NRIX
$2.71B
$11.9M 1.47%
810,253
+120,141
+17% +$1.29M
ATXS
20
DELISTED
Astria Therapeutics
ATXS
$11.9M 1.47%
845,606
-620,859
-42% -$7.73M
NUVL
21
DELISTED
Nuvalent
NUVL
$11.3M 1.39%
150,000
-25,000
-14% -$1.99M
AXSM icon
22
Axsome Therapeutics
AXSM
$10.8B
$11.2M 1.38%
139,758
+89,758
+180% +$7.53M
APLS
23
DELISTED
Apellis Pharmaceuticals
APLS
$9.7M 1.2%
165,000
+90,000
+120% +$5.74M
CNTA
24
DELISTED
Centessa Pharmaceuticals
CNTA
$9.39M 1.16%
830,546
+34,817
+4% +$330K
IMVT icon
25
Immunovant
IMVT
$8.11B
$9.21M 1.14%
285,000
-60,000
-17% -$2.19M
1
2 3 4 5

Similar funds

BCP
BSN Capital Partners London, United Kingdom $2.21B AUM 22.85% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $2.21B AUM 28.75% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $2.22B AUM 23.18% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2.22B AUM 32.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.2B AUM 46.08% 1-Year Est. Return

Affinity Asset Advisors's Q1 2024 Portfolio in Review

As of Q1 2024, Affinity Asset Advisors held 122 positions worth $808M, up 48% from $548M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Affinity Asset Advisors withdrew a net $29.2M in Q1 2024, closing 27 positions and reducing 16 holdings. Its most notable exit was Immunogen Inc, an estimated $41.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 86% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Affinity Asset Advisors opened a new position in Vera Therapeutics worth $20.3M.

  • Affinity Asset Advisors's largest Q1 2024 buy was Vera Therapeutics: 470,000 shares worth $20.3M.
  • Affinity Asset Advisors added most to Xenon Pharmaceuticals in Q1 2024, an estimated $17.4M increase.
  • Affinity Asset Advisors's biggest Q1 2024 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $18.9M.
  • Affinity Asset Advisors fully exited Immunogen Inc in Q1 2024, selling an estimated $41.6M.
  • Affinity Asset Advisors's ten largest holdings make up 40% of its $808M portfolio in Q1 2024.
  • Affinity Asset Advisors opened 39 new positions and closed 27 in Q1 2024.
  • Affinity Asset Advisors's portfolio value rose 48% quarter-over-quarter to $808M.

Based on Affinity Asset Advisors's 13F filing for Q1 2024, filed 14 May 2024.